India's largest manufacturer of aliphatic amines and methylamines, serving pharma, agro and EV battery makers.
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 652 | 888 | 1.2k | 1.5k | 1.7k | 1.8k | 1.9k | 2.0k |
| Borrowings | 260 | 127 | 101 | 58 | 20 | 11 | 31 | 133 |
| Other Liabilities | 195 | 289 | 395 | 351 | 405 | 396 | 418 | 633 |
| Total Liabilities | 1.1k | 1.3k | 1.7k | 2.0k | 2.1k | 2.3k | 2.3k | 2.7k |
| AssetsFixed Assets | 573 | 543 | 681 | 780 | 896 | 1.0k | 1.1k | 1.0k |
| CWIP | 46 | 173 | 141 | 113 | 205 | 238 | 339 | 512 |
| Investments | 48 | 0 | 0 | 73 | 0 | 0 | 0 | 0 |
| Other Assets | 446 | 594 | 923 | 996 | 1.0k | 1.0k | 935 | 1.2k |
| Total Assets | 1.1k | 1.3k | 1.7k | 2.0k | 2.1k | 2.3k | 2.3k | 2.7k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 94 | 144 | 110 | 220 | 354 | 334 | 255 | 184 |
| Cash from Investing | -119 | -130 | -62 | -147 | -210 | -274 | -139 | -344 |
| Cash from Financing | 21 | -26 | -37 | -57 | -81 | -75 | -49 | 85 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -75 | 83 | -21 | 72 | 234 | 82 | 69 | -186 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (31.8×) and current (33.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -25.2% growth and a 32× exit, ₹2138 only delivers your return if you pay ₹170. The price is currently baking in 19% growth.
EPS grows -25.2%/yr for 5 years, then fades to 6% over 2, exits at 32×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -25.2% | 47.13 |
| FY28 | -25.2% | 35.25 |
| FY29 | -25.2% | 26.37 |
| FY30 | -25.2% | 19.72 |
| FY31 | -25.2% | 14.75 |
| FY32 | -9.6% ·fade | 13.34 |
| FY33 | 6.0% ·fade | 14.14 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.